BiotechTube
Swan NeuroTech

Swan NeuroTech

San Diego, United States· Est.
swanneurotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.2M

Overview

Swan NeuroTech is a private, pre-revenue biotech company advancing a novel platform for peripheral nerve regeneration. The company's technology centers on tunable polymer-based nerve graft conduits integrated with controlled drug delivery via polymer microspheres, manufactured using a proprietary additive manufacturing process. Targeting a significant unmet medical need with an estimated $20B annual US healthcare cost burden, Swan NeuroTech is in the pre-clinical development stage, leveraging a team and advisory board with strong expertise in regenerative medicine, polymer science, and clinical neurology. The company appears to be in a foundational R&D phase, building its technology portfolio and team.

Peripheral Nerve Injuries

Technology Platform

Integrated platform for nerve regeneration combining tunable biodegradable polymer conduits with controlled drug delivery via polymer microspheres, manufactured using proprietary additive manufacturing (polymer dipping) technology.

Funding History

1
Total raised:$5.2M
Seed$5.2M

Opportunities

The company targets a large, underserved market with an estimated $20B annual US cost burden from peripheral nerve injuries.
Its integrated platform (scaffold + drug delivery) addresses key limitations of current treatments and could become a new standard of care.
The flexible technology may also allow expansion into adjacent areas of neural or soft tissue repair.

Risk Factors

As a pre-revenue, pre-clinical start-up, the company faces high technical risk in proving efficacy, significant regulatory hurdles for a combination product, and total dependence on securing sufficient funding to advance through costly development stages.
It also operates in a competitive landscape with other academic and commercial entities targeting nerve regeneration.

Competitive Landscape

The nerve repair market includes existing hollow conduit products, autograft standards, and several companies/academic groups developing advanced biomaterial scaffolds, growth factor delivery systems, and cell-based therapies. Swan NeuroTech competes by combining tunable polymer mechanics with controlled drug release in a single, manufacturable implant, aiming for a differentiated therapeutic profile.

More companies in Regenerative Medicine →More companies in United States →